Mycophenolate mofetil (MMF), the ester prodrug of mycophenolic acid, has been increasingly used in HCT.

There are very limited data on dose–exposure relationships in pediatric patients.

Individualized MMF dosing by targeting AUC of mycophenolic acid is feasible and effective in the early phase after allogeneic HCT.

MMF can be safely given by continuous intravenous infusion in children with excellent engraftment and low rates of acute and chronic GVHD.